Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD, MAD, and Food Effect Study of MF-300 in Healthy Participants
NCT07613684Phase 1Completed
- Sponsor
- Epirium Bio
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MF-300 (5 arms), sponsored by Epirium Bio. Primary endpoints: Treatment-Emergent Adverse Events at Day 13, Serious Adverse Events at Day 13 and 1 more. Started Dec 2024; status: completed.
02
Drugs
MF-300
Beyond the preview
Go deeper on NCT07613684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613684.